A new ICB relatlimab-rmbw (lymphocyte activation gene-3 (LAG-3)-directed mAb) was approved by the FDA in combination with nivolumab for unresectable or metastatic melanoma on March 18, 2022 [795]. The gene discussed is LAG3; the disease is metastatic melanoma.